Bioinformatic analysis of neurotropic HIV envelope sequences identifies polymorphisms in the gp120 bridging sheet that increase macrophage-tropism through enhanced interactions with CCR5

Virology

Volumn 481, Issue , 2015, Pages 210-222

  Mefford, Megan E ^a   Kunstman, Kevin ^b   Wolinsky, Steven M ^b   Gabuzda, Dana ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bridging sheet; CCR5; CD4; Envelope; HIV; Macrophage; Tropism; V1 V2 stem

Indexed keywords

CHEMOKINE RECEPTOR CCR5; GLYCAN; GLYCOPROTEIN GP 120; PROTEIN BINDING;

AMINO ACID SEQUENCE; ARTICLE; BIOINFORMATICS; BRAIN INFECTION; CD4+ T LYMPHOCYTE; CELL FUSION; CONTROLLED STUDY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MACROPHAGE; NEUROTROPISM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN POLYMORPHISM; T LYMPHOCYTE; TROPISM; VIRUS ENVELOPE; VIRUS REPLICATION; VIRUS STRAIN; BIOLOGY; BRAIN; CHEMISTRY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; SEQUENCE ALIGNMENT; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL TROPISM; VIROLOGY;

AMINO ACID SEQUENCE; BRAIN; COMPUTATIONAL BIOLOGY; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, CCR5; SEQUENCE ALIGNMENT; VIRAL TROPISM;

EID: 84925047739     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2015.01.032     Document Type: Article

References (90)

1. Anand R., Thayer R., Srinivasan A., Nayyar S., Gardner M., Luciw P., Dandekar S. Biological and molecular characterization of human immunodeficiency virus (HIV-1BR) from the brain of a patient with progressive dementia. Virology 1989, 168:79-89.
2. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA 1999, 96:5698-5703.
3. Bannert N., Schenten D., Craig S., Sodroski J. The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses. J. Virol. 2000, 74:10984-10993.
4. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 2004, 78:13232-13252.
5. Bowley D.R., Labrijn A.F., Zwick M.B., Burton D.R. Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage. Protein Eng. Des. Sel. 2007, 20:81-90.
6. Brown R.J., Peters P.J., Caron C., Gonzalez-Perez M.P., Stones L., Ankghuambom C., Pondei K., McClure C.P., Alemnji G., Taylor S., Sharp P.M., Clapham P.R., Ball J.K. Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors. J. Virol. 2011, 85:6024-6037.
7. Chen B., Vogan E.M., Gong H., Skehel J.J., Wiley D.C., Harrison S.C. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005, 433:834-841.
8. Cheng-Mayer C., Liu R., Landau N.R., Stamatatos L. Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J. Virol. 1997, 71:1657-1661.
9. Chenine A.L., Pion M., Matouskova E., Gondois-Rey F., Vigne R., Hirsch I. Adaptation of a CXCR4-using human immunodeficiency type 1 NDK virus in intestinal cells is associated with CD4-independent replication. Virology 2002, 304:403-414.
10. Dayton A.I. Hitting HIV where it hides. Retrovirology 2008, 5:15.
11. Dey B., Pancera M., Svehla K., Shu Y., Xiang S.H., Vainshtein J., Li Y., Sodroski J., Kwong P.D., Mascola J.R., Wyatt R. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J. Virol. 2007, 81:5579-5593.
12. Doms R.W., Trono D. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev. 2000, 14:2677-2688.
13. Duenas-Decamp M.J., Peters P., Burton D., Clapham P.R. Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J. Virol. 2008, 82:5807-5814.
14. Duenas-Decamp M.J., Peters P.J., Burton D., Clapham P.R. Determinants flanking the CD4 binding loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes. J. Virol. 2009, 83:2575-2583.
15. Duncan C.J., Sattentau Q.J. Viral determinants of HIV-1 macrophage tropism. Viruses 2011, 3:2255-2279.
16. Dunfee R., Thomas E.R., Gorry P.R., Wang J., Ancuta P., Gabuzda D. Mechanisms of HIV-1 neurotropism. Curr. HIV Res. 2006, 4:267-278.
17. Dunfee R.L., Thomas E.R., Gorry P.R., Wang J., Taylor J., Kunstman K., Wolinsky S.M., Gabuzda D. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc. Natl. Acad. Sci. USA 2006, 103:15160-15165.
18. Dunfee R.L., Thomas E.R., Wang J., Kunstman K., Wolinsky S.M., Gabuzda D. Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology 2007, 367:222-234.
19. Etemad-Moghadam B., Sun Y., Nicholson E.K., Fernandes M., Liou K., Gomila R., Lee J., Sodroski J. Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J. Virol. 2000, 74:4433-4440.
20. Gartner S., McDonald R.A., Hunter E.A., Bouwman F., Liu Y., Popovic M. Gp120 sequence variation in brain and in T-lymphocyte human immunodeficiency virus type 1 primary isolates. J. Hum. Virol. 1997, 1:3-18.
21. Gorry P.R., Bristol G., Zack J.A., Ritola K., Swanstrom R., Birch C.J., Bell J.E., Bannert N., Crawford K., Wang H., Schols D., De Clercq E., Kunstman K., Wolinsky S.M., Gabuzda D. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J. Virol. 2001, 75:10073-10089.
22. Gorry P.R., Churchill M., Crowe S.M., Cunningham A.L., Gabuzda D. Pathogenesis of macrophage tropic HIV-1. Curr. HIV Res. 2005, 3:53-60.
23. Gorry P.R., Taylor J., Holm G.H., Mehle A., Morgan T., Cayabyab M., Farzan M., Wang H., Bell J.E., Kunstman K., Moore J.P., Wolinsky S.M., Gabuzda D. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J. Virol. 2002, 76:6277-6292.
24. Gray L., Sterjovski J., Churchill M., Ellery P., Nasr N., Lewin S.R., Crowe S.M., Wesselingh S.L., Cunningham A.L., Gorry P.R. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology 2005, 337:384-398.
25. Gray L.R., Gabuzda D., Cowley D., Ellett A., Chiavaroli L., Wesselingh S.L., Churchill M.J., Gorry P.R. CD4 and MHC class 1 down-modulation activities of nef alleles from brain- and lymphoid tissue-derived primary HIV-1 isolates. J. Neurovirol. 2011, 17:82-91.
26. Haim H., Si Z., Madani N., Wang L., Courter J.R., Princiotto A., Kassa A., DeGrace M., McGee-Estrada K., Mefford M., Gabuzda D., Smith A.B., Sodroski J. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog. 2009, 5:e1000360.
27. Haim H., Strack B., Kassa A., Madani N., Wang L., Courter J.R., Princiotto A., McGee K., Pacheco B., Seaman M.S., Smith A.B., Sodroski J. Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. PLoS Pathog. 2011, 7:e1002101.
28. Huang K.J., Alter G.M., Wooley D.P. The reverse transcriptase sequence of human immunodeficiency virus type 1 is under positive evolutionary selection within the central nervous system. J. Neurovirol. 2002, 8:281-294.
29. Huang X., Jin W., Hu K., Luo S., Du T., Griffin G.E., Shattock R.J., Hu Q. Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. Virology 2012, 423:97-106.
30. Hughes E.S., Bell J.E., Simmonds P. Investigation of the dynamics of the spread of human immunodeficiency virus to brain and other tissues by evolutionary analysis of sequences from the p17gag and env genes. J. Virol. 1997, 71:1272-1280.
31. Igarashi T., Imamichi H., Brown C.R., Hirsch V.M., Martin M.A. The emergence and characterization of macrophage-tropic SIV/HIV chimeric viruses (SHIVs) present in CD4+ T cell-depleted rhesus monkeys. J. Leukoc. Biol. 2003, 74:772-780.
32. Johnston S.H., Lobritz M.A., Nguyen S., Lassen K., Delair S., Posta F., Bryson Y.J., Arts E.J., Chou T., Lee B. A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J. Virol. 2009, 83:11016-11026.
33. Julien J.P., Cupo A., Sok D., Stanfield R.L., Lyumkis D., Deller M.C., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., Ward A.B., Wilson I.A. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477-1483.
34. Keele B.F., Tazi L., Gartner S., Liu Y., Burgon T.B., Estes J.D., Thacker T.C., Crandall K.A., McArthur J.C., Burton G.F. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J. Virol. 2008, 82:5548-5561.
35. Kolchinsky P., Kiprilov E., Bartley P., Rubinstein R., Sodroski J. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J. Virol. 2001, 75:3435-3443.
36. Kolchinsky P., Kiprilov E., Sodroski J. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J. Virol. 2001, 75:2041-2050.
37. Kuhmann S.E., Platt E.J., Kozak S.L., Kabat D. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J. Virol. 2000, 74:7005-7015.
38. Kwong P.D., Wyatt R., Majeed S., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 2000, 8:1329-1339.
39. Lamers S.L., Salemi M., Galligan D.C., de Oliveira T., Fogel G.B., Granier S.C., Zhao L., Brown J.N., Morris A., Masliah E., McGrath M.S. Extensive HIV-1 intra-host recombination is common in tissues with abnormal histopathology. PloS One 2009, 4:e5065.
40. Le Douce V., Herbein G., Rohr O., Schwartz C. Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology 2010, 7:32.
41. Li Y., Cleveland B., Klots I., Travis B., Richardson B.A., Anderson D., Montefiori D., Polacino P., Hu S.L. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J. Virol. 2008, 82:638-651.
42. Liu J., Bartesaghi A., Borgnia M.J., Sapiro G., Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109-113.
43. Liu L., Cimbro R., Lusso P., Berger E.A. Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer. Proc. Natl. Acad. Sci. USA 2011, 108:20148-20153.
44. Liu Y., Tang X.P., McArthur J.C., Scott J., Gartner S. Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J. Neurovirol. 2000, 6(Suppl 1):S70-S81.
45. Ly A., Stamatatos L. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J. Virol. 2000, 74:6769-6776.
46. Lyumkis D., Julien J.P., de Val N., Cupo A., Potter C.S., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., Carragher B., Wilson I.A., Ward A.B. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1484-1490.
47. Madani N., Perdigoto A.L., Srinivasan K., Cox J.M., Chruma J.J., LaLonde J., Head M., Smith A.B., Sodroski J.G. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J. Virol. 2004, 78:3742-3752.
48. Martin-Garcia J., Cao W., Varela-Rohena A., Plassmeyer M.L., Gonzalez-Scarano F. HIV-1 tropism for the central nervous system: brain-derived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor. Virology 2006, 346:169-179.
49. Mefford M.E., Gorry P.R., Kunstman K., Wolinsky S.M., Gabuzda D. Bioinformatic prediction programs underestimate the frequency of CXCR4 usage by R5×4 HIV type 1 in brain and other tissues. AIDS Res. Hum. Retroviruses 2008, 24:1215-1220.
50. Monken C.E., Wu B., Srinivasan A. High resolution analysis of HIV-1 quasispecies in the brain. AIDS 1995, 9:345-349.
51. Moore J.P., Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 1996, 70:1863-1872.
52. Moore P.L., Gray E.S., Choge I.A., Ranchobe N., Mlisana K., Abdool Karim S.S., Williamson C., Morris L., Team C.S. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J. Virol. 2008, 82:1860-1869.
53. Morris A., Marsden M., Halcrow K., Hughes E.S., Brettle R.P., Bell J.E., Simmonds P. Mosaic structure of the human immunodeficiency virus type 1 genome infecting lymphoid cells and the brain: evidence for frequent in vivo recombination events in the evolution of regional populations. J. Virol. 1999, 73:8720-8731.
54. Musich T., Peters P.J., Duenas-Decamp M.J., Gonzalez-Perez M.P., Robinson J., Zolla-Pazner S., Ball J.K., Luzuriaga K., Clapham P.R. A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection. J. Virol. 2011, 85:2397-2405.
55. O'Connell O., Repik A., Reeves J.D., Gonzalez-Perez M.P., Quitadamo B., Anton E.D., Duenas-Decamp M., Peters P., Lin R., Zolla-Pazner S., Corti D., Wallace A., Wang S., Kong X.P., Lu S., Clapham P.R. Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism. J. Virol. 2013, 87:187-198.
56. O'Rourke S.M., Schweighardt B., Phung P., Mesa K.A., Vollrath A.L., Tatsuno G.P., To B., Sinangil F., Limoli K., Wrin T., Berman P.W. Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies. J. Virol. 2012, 86:12105-12114.
57. Ohagen A., Devitt A., Kunstman K.J., Gorry P.R., Rose P.P., Korber B., Taylor J., Levy R., Murphy R.L., Wolinsky S.M., Gabuzda D. Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J. Virol. 2003, 77:12336-12345.
58. Otto C., Puffer B.A., Pohlmann S., Doms R.W., Kirchhoff F. Mutations in the C3 region of human and simian immunodeficiency virus envelope have differential effects on viral infectivity, replication, and CD4-dependency. Virology 2003, 315:292-302.
59. Pan Y., Ma B., Nussinov R. CD4 binding partially locks the bridging sheet in gp120 but leaves the beta2/3 strands flexible. J. Mol. Biol. 2005, 350:514-527.
60. Pantophlet R., Ollmann Saphire E., Poignard P., Parren P.W., Wilson I.A., Burton D.R. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 2003, 77:642-658.
61. Peters P.J., Bhattacharya J., Hibbitts S., Dittmar M.T., Simmons G., Bell J., Simmonds P., Clapham P.R. Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. J. Virol. 2004, 78:6915-6926.
62. Peters P.J., Duenas-Decamp M.J., Sullivan W.M., Brown R., Ankghuambom C., Luzuriaga K., Robinson J., Burton D.R., Bell J., Simmonds P., Ball J., Clapham P.R. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. Retrovirology 2008, 5:5.
63. Peters P.J., Duenas-Decamp M.J., Sullivan W.M., Clapham P.R. Variation of macrophage tropism among HIV-1 R5 envelopes in brain and other tissues. J. Neuroimmune Pharmacol. 2007, 2:32-41.
64. Pierson T., McArthur J., Siliciano R.F. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu. Rev. Immunol. 2000, 18:665-708.
65. Pikora C., Wittish C., Desrosiers R.C. Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4. J. Virol. 2005, 79:12575-12583.
66. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72:2855-2864.
67. Pond S.L., Frost S.D. A genetic algorithm approach to detecting lineage-specific variation in selection pressure. Mol. Biol. Evol. 2005, 22:478-485.
68. Pond S.L., Frost S.D., Grossman Z., Gravenor M.B., Richman D.D., Brown A.J. Adaptation to different human populations by HIV-1 revealed by codon-based analyses. PLoS Comput. Biol. 2006, 2:e62.
69. Pond S.L.K., Poon A.F.Y., Zarate S., Smith D.M., Little S.J., Pillai S.K., Ellis R.J., Wong J.K., Leigh Brown A.J., Richman D.D., Frost S.D.W. Estimating selection pressures on HIV-1 using phylogenetic likelihood models. Stat. Med. 2008, 27:4779-4789.
70. Poon A.F., Frost S.D., Pond S.L. Detecting signatures of selection from DNA sequences using Datamonkey. Methods Mol. Biol. 2009, 537:163-183.
71. Poon A.F., Lewis F.I., Pond S.L., Frost S.D. Evolutionary interactions between N-linked glycosylation sites in the HIV-1 envelope. PLoS Comput. Biol. 2007, 3:e11.
72. Power C., McArthur J.C., Johnson R.T., Griffin D.E., Glass J.D., Dewey R., Chesebro B. Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence. Curr. Top. Microbiol. Immunol. 1995, 202:89-104.
73. Puffer B.A., Altamura L.A., Pierson T.C., Doms R.W. Determinants within gp120 and gp41 contribute to CD4 independence of SIV Envs. Virology 2004, 327:16-25.
74. Reeves J.D., Gallo S.A., Ahmad N., Miamidian J.L., Harvey P.E., Sharron M., Pohlmann S., Sfakianos J.N., Derdeyn C.A., Blumenthal R., Hunter E., Doms R.W. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. USA 2002, 99:16249-16254.
75. Richards K.H., Aasa-Chapman M.M., McKnight A., Clapham P.R. Modulation of HIV-1 macrophage-tropism among R5 envelopes occurs before detection of neutralizing antibodies. Retrovirology 2010, 7:48.
76. Rizzuto C.D., Wyatt R., Hernandez-Ramos N., Sun Y., Kwong P.D., Hendrickson W.A., Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998, 280:1949-1953.
77. Saphire E.O., Parren P.W., Barbas C.F., Burton D.R., Wilson I.A. Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: an antibody that broadly neutralizes primary isolates of HIV-1. Acta Crystallogr. D: Biol. Crystallogr. 2001, 57:168-171.
78. Shapshak P., Segal D.M., Crandall K.A., Fujimura R.K., Zhang B.T., Xin K.Q., Okuda K., Petito C.K., Eisdorfer C., Goodkin K. Independent evolution of HIV type 1 in different brain regions. AIDS Res. Hum. Retroviruses 1999, 15:811-820.
79. Si Z., Madani N., Cox J.M., Chruma J.J., Klein J.C., Schon A., Phan N., Wang L., Biorn A.C., Cocklin S., Chaiken I., Freire E., Smith A.B., Sodroski J.G. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Natl. Acad. Sci. USA 2004, 101:5036-5041.
80. Smurzynski M., Wu K., Letendre S., Robertson K., Bosch R.J., Clifford D.B., Evans S., Collier A.C., Taylor M., Ellis R. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011, 25:357-365.
81. Sterjovski J., Churchill M.J., Ellett A., Gray L.R., Roche M.J., Dunfee R.L., Purcell D.F., Saksena N., Wang B., Sonza S., Wesselingh S.L., Karlsson I., Fenyo E.M., Gabuzda D., Cunningham A.L., Gorry P.R. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 2007, 4:89.
82. Sterjovski J., Roche M., Churchill M.J., Ellett A., Farrugia W., Gray L.R., Cowley D., Poumbourios P., Lee B., Wesselingh S.L., Cunningham A.L., Ramsland P.A., Gorry P.R. An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology 2010, 404:269-278.
83. Thomas E.R., Dunfee R.L., Stanton J., Bogdan D., Taylor J., Kunstman K., Bell J.E., Wolinsky S.M., Gabuzda D. Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology 2007, 360:105-119.
84. Walter B.L., Wehrly K., Swanstrom R., Platt E., Kabat D., Chesebro B. Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophages. J. Virol. 2005, 79:4828-4837.
85. Wang J., Crawford K., Yuan M., Wang H., Gorry P.R., Gabuzda D. Regulation of CC chemokine receptor 5 and CD4 expression and human immunodeficiency virus type 1 replication in human macrophages and microglia by T helper type 2 cytokines. J. Infect. Dis. 2002, 185:885-897.
86. Wang T.H., Donaldson Y.K., Brettle R.P., Bell J.E., Simmonds P. Identification of shared populations of human immunodeficiency virus type 1 infecting microglia and tissue macrophages outside the central nervous system. J. Virol. 2001, 75:11686-11699.
87. Watkins J.D., Diaz-Rodriguez J., Siddappa N.B., Corti D., Ruprecht R.M. Efficiency of neutralizing antibodies targeting the CD4-binding site: influence of conformational masking by the V2 loop in R5-tropic clade C simian-human immunodeficiency virus. J. Virol. 2011, 85:12811-12814.
88. Yen P.J., Herschhorn A., Haim H., Salas I., Gu C., Sodroski J., Gabuzda D. Loss of a conserved N-linked glycosylation site in the SIV envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission. J. Virol. 2015, 88:5014-5028.
89. Zhang W., Godillot A.P., Wyatt R., Sodroski J., Chaiken I. Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4. Biochemistry 2001, 40:1662-1670.
90. Zhu C.B., Zhu L., Holz-Smith S., Matthews T.J., Chen C.H. The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012. Proc. Natl. Acad. Sci. USA 2001, 98:15227-15232.